teva report dilut ep revenu compar street
estim respect manag reiter guidanc
rang prior expect regard modest eros gener
busi play continu take glass-is-half-ful approach teva though
copaxon eros pick strong visibl continu ramp ajovi
austedo render less problemat time help drive long-term ebitda
stabil eventu growth said drive continu caution toward
share ebitda hit trough potenti implic regard
pace de-lever particularli ebitda reiter neutral
rate slightli lower pt owe modest model revis
ajovi track nice overli worri gross-to-net spread
metric teva point regard share anti-cgrp volum new-to-
brand prescript rx share neighborhood dovetail check point
steadi ramp overal volum expect ramp refer piec
highlight survey migrain specialist challeng cours
heavi subsid patient out-of-pocket cost main driver
wide gap gross net sale estim north
base total vial dispens per iqvia list price per vial spread
undoubtedli narrow time manag made clear expect
settl north good bit higher initi expect closer
alway struck us unrealist given tough competitor landscap heavi
contract said would interpret neg space essenti
share grab though good news patient pie expand net
sale easili quit signific even wide
faster pace copaxon eros that bad thing manag
guid annual run rate around copaxon compar
previou expect approxim commentari surpris us given
teva share copaxon mg/ml volum declin around
begin around end take dynam
sooner product import minim better term
drive visibl long-term ebitda stabil eventu growth
keep eye forteo gener forteo gener consequenti
new launch reflect extent guid brand
sale teva expect launch though hedg somewhat competit
dynam awar least one anoth competitor queue nonetheless
believ launch gener market format limit competit
ep disc
debt total capit
risk includ copaxon competit gener price risk
teva leader gener neurology-focus drug
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
note street estim
compani report factset research pjc estim
compani report pjc estim
page
million except per share itemsactualspjc estimatesstreet estimatesnorth america market non-cor pjc except per exhibit
account fact prescript ajovi written quarterli dose vial monthli dose vial
compani report pjc estim
page
sale salestot anti-cgrp monoclon antibodi mab retail sequenti total ajovi sequenti teva retail ajovi per per per per ajovi exhibit
note prior estim comparison may applic due pjc updat report line item
consensu estim
includ sale proair teva ag pjc prior estim includ sale ag
compani report factset research pjc estim
page
million except per america market non-cor consensu incom expens net share consensu teva quarterli annual incom statement
million except ep
sale
sell gener administr
incom loss tax
cog product revenu
expens total revenu
sell gener administr
sell gener administr
teva alter revenu report methodolog result histor may reflect pjc estim
proprietari piper jaffray may
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
